Controlling the Immune Suppressor: Transcription Factors and MicroRnAs Regulating CD73/NT5E

被引:79
作者
Kordass, Theresa [1 ,2 ]
Osen, Wolfram [1 ]
Eichmueller, Stefan B. [1 ]
机构
[1] German Canc Res Ctr, GMP & T Cell Therapy Unit, Heidelberg, Germany
[2] Heidelberg Univ, Fac Biosci, Heidelberg, Germany
关键词
checkpoint molecule; CD73; NT5E; microRNA; transcription factor; T cell; tumor; A2A receptor; HUMAN BREAST-CANCER; ENDOTHELIAL BARRIER FUNCTION; CELL LUNG-CANCER; MELANOMA-CELLS; IN-VIVO; ECTO-5'-NUCLEOTIDASE CD73; IMMUNOSUPPRESSIVE ACTIVITY; PROGNOSTIC BIOMARKER; INTESTINAL EPITHELIA; PROMOTES RESISTANCE;
D O I
10.3389/fimmu.2018.00813
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The NT5E (CD73) molecule represents an ecto-5'-nucleotidase expressed on the cell surface of various cell types. Hydrolyzing extracellular adenosine monophosphate into adenosine and inorganic phosphate, NT5E performs numerous homeostatic functions in healthy organs and tissues. Importantly, NT5E can act as inhibitory immune checkpoint molecule, since free adenosine generated by NT5E inhibits cellular immune responses, thereby promoting immune escape of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules regulating gene expression on posttranscriptional level through binding to mRNAs, resulting in translational repression or degradation of the targeted mRNA molecule. In tumor cells, miRNA expression patterns are often altered which in turn might affect NT5E surface expression and eventually influence the efficacy of antitumor immune responses. This review describes the diverse roles of NT5E, summarizes current knowledge about transcription factors controlling NT5E expression, and highlights the significance of miRNAs involved in the posttranscriptional regulation of NT5E expression.
引用
收藏
页数:8
相关论文
共 92 条
[1]   Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells [J].
Airas, L ;
Niemela, J ;
Salmi, M ;
Puurunen, T ;
Smith, DJ ;
Jalkanen, S .
JOURNAL OF CELL BIOLOGY, 1997, 136 (02) :421-431
[2]   CD73 IS INVOLVED IN LYMPHOCYTE BINDING TO THE ENDOTHELIUM - CHARACTERIZATION OF LYMPHOCYTE VASCULAR ADHESION PROTEIN-2 IDENTIFIES IT AS CD73 [J].
AIRAS, L ;
HELLMAN, J ;
SALMI, M ;
BONO, P ;
PUURUNEN, T ;
SMITH, DJ ;
JALKANEN, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1603-1608
[3]   CD73 Is Expressed by Human Regulatory T Helper Cells and Suppresses Proinflammatory Cytokine Production and Helicobacter felis-Induced Gastritis in Mice [J].
Alam, Mohammad S. ;
Kurtz, Courtney C. ;
Rowlett, Robert M. ;
Reuter, Brian K. ;
Wiznerowicz, Elizabeth ;
Das, Soumita ;
Linden, Joel ;
Crowe, Sheila E. ;
Ernst, Peter B. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (04) :494-504
[4]   The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets [J].
Allard, Bertrand ;
Longhi, Maria Serena ;
Robson, Simon C. ;
Stagg, John .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :121-144
[5]   Immunosuppressive activities of adenosine in cancer [J].
Allard, Bertrand ;
Beavis, Paul A. ;
Darcy, Phillip K. ;
Stagg, John .
CURRENT OPINION IN PHARMACOLOGY, 2016, 29 :7-16
[6]   Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer [J].
Allard, Bertrand ;
Turcotte, Martin ;
Stagg, John .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (08) :863-881
[7]   Anti-CD73 therapy impairs tumor angiogenesis [J].
Allard, Bertrand ;
Turcotte, Martin ;
Spring, Kathleen ;
Pommey, Sandra ;
Royal, Isabelle ;
Stagg, John .
INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) :1466-1473
[8]   Ecto-5′-nucleotidase/CD73 knockdown increases cell migration and mRNA level of collagen I in a hepatic stellate cell line [J].
Andrade, Claudia M. B. ;
Lopez, Patricia L. C. ;
Noronha, Bruno T. ;
Wink, Marcia R. ;
Borojevic, Radovan ;
Margis, Rogerio ;
Lenz, Guido ;
Battastini, Ana Maria O. ;
Guma, Fatima C. R. .
CELL AND TISSUE RESEARCH, 2011, 344 (02) :279-286
[9]   Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies [J].
Antonio, Luca ;
Novitskiy, Sergey V. ;
Sachsenmeier, Kris F. ;
Fornai, Matteo ;
Blandizzi, Corrado ;
Hasko, Gyorgy .
DRUG DISCOVERY TODAY, 2017, 22 (11) :1686-1696
[10]   Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities [J].
Antonioli, Luca ;
Yegutkin, Gennady G. ;
Pacher, Pal ;
Blandizzi, Corrado ;
Hasko, Gyorgy .
TRENDS IN CANCER, 2016, 2 (02) :95-109